论文部分内容阅读
目的探讨CTOP与CHOP方案治疗老年非霍奇金淋巴瘤(NHL)的临床疗效,并进行对比分析。方法我院108例患者随机分为A组与B组两组患者,A组患者实施CTOP治疗方案(环磷酰胺+吡柔比星+长春新碱+强的松),B患者实施CHOP治疗方案,在A组实施的治疗方案上,以同等剂量的阿霉素(ADM)取代吡柔比星(THP),其余与A相同。在治疗4周之后,根据患者的具体病情进行放疗或加用博来霉素化疗。结果通过对两组患者的治疗,A组完全缓解(CR)72.2%,T淋巴细胞瘤CR76.9%,2年的总生存率为51.9%;B组患者完全缓解(CR)63.0%,T淋巴细胞瘤CR47.1%,2年的总生存率为50.0%。A、B两组患者在治疗之后,2年生存率以及CR率的比较差异无统计学意义(P>0.05);T淋巴细胞瘤,A组方案明显优于B组方案,脱发、心脏毒性差异具有统计学意义(P<0.05)。结论 CTOP的治疗方案明显更加适合老年非霍奇金淋巴瘤的治疗,其不良反应、毒副作用明显低于CHOP的治疗方案,提高患者的生活质量,值得在临床上广泛应用。
Objective To investigate the clinical effects of CTOP and CHOP regimen in the treatment of elderly non-Hodgkin’s lymphoma (NHL) and compare the results. Methods A total of 108 patients in our hospital were randomly divided into two groups: group A and group B, group A received CTOP (cyclophosphamide + pirarubicin + vincristine + prednisone), and group B received CHOP In the group A treatment regimen, the same dose of doxorubicin (ADM) instead of pirarubicin (THP), the rest with A the same. After 4 weeks of treatment, according to the specific condition of patients with radiotherapy or chemotherapy with bleomycin. Results The complete remission (CR) was 72.2% in group A, CR was 76.9% in group T, and the overall survival rate was 51.9% at 2 years. The complete remission (CR) in group B was 63.0% Lymphoma CR47.1%, 2-year overall survival rate was 50.0%. There was no significant difference in 2-year survival rate and CR rate between A and B groups after treatment (P> 0.05). The T-cell lymphoma, A group was significantly better than B group, alopecia, cardiotoxicity Statistically significant (P <0.05). Conclusion The treatment of CTOP is obviously more suitable for the treatment of elderly non-Hodgkin’s lymphoma. The adverse reactions and side effects of CTOP are obviously lower than that of CHOP, and the quality of life of patients is improved. It is worth to be widely used clinically.